AIA Group Ltd Has $4.15 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AIA Group Ltd boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,722 shares of the biopharmaceutical company’s stock after buying an additional 565 shares during the period. AIA Group Ltd’s holdings in Regeneron Pharmaceuticals were worth $4,147,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Sunbelt Securities Inc. acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. Sutton Wealth Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares in the last quarter. Finally, Bruce G. Allen Investments LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $40,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on REGN. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Royal Bank of Canada reissued an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $976.41.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the sale, the director now owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $3.27 during midday trading on Thursday, hitting $897.92. The company’s stock had a trading volume of 277,592 shares, compared to its average volume of 492,312. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company has a 50-day moving average price of $955.19 and a two-hundred day moving average price of $890.52. The company has a market cap of $98.56 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the firm earned $10.96 EPS. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.58 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.